Alprazolam vs Lorazepam: Nutrient Depletion Comparison
Compare YOUR medications' depletionsFree, 10 seconds →
At a Glance
Alprazolam binds the benzodiazepine site on GABA-A receptors, potentiating chloride influx that dampens neuronal firing and suppresses pineal melatonin synthesis. CTD documents 78 gene interactions for alprazolam, including significant effects on CYP3A4, the enzyme primarily responsible for its metabolism. This CYP3A4 induction accelerates hydroxylation of 25-hydroxyvitamin D, depleting circulating vitamin D and subsequently reducing calcium absorption that depends on vitamin D-mediated intestinal transport.
Alprazolam achieves 80–90% oral bioavailability with peak plasma levels in 1–2 hours and a half-life of 11.2 hours, necessitating two to three daily doses that create repeated peak-trough cycles in blood levels.
- ✓Rapid onset (15–30 minutes) provides fast panic attack relief
- ✓Shorter half-life means less next-day cognitive impairment
- ✓ChEMBL documents 208 RCTs across 30,200 patients — the most extensively studied benzodiazepine
- ✓Lower protein binding (71%) reduces accumulation risk in patients on multiple medications
- ✗Short half-life drives frequent withdrawal-rebound cycles that worsen nutrient depletion
- ✗Strong CYP3A4 involvement creates more drug interactions and faster vitamin D clearance
- ✗FAERS logs 116,446 adverse event reports with an 18.1% death-associated rate
- ✗Rapid tolerance development frequently leads to dose escalation within the first month
Patients who need rapid-acting relief for acute panic episodes and have a clear short-term treatment plan with supervised tapering.
Lorazepam binds the same GABA-A benzodiazepine site but is metabolized primarily through direct hepatic glucuronidation — bypassing the CYP450 enzyme system almost entirely. CTD identifies 50 gene interactions for lorazepam, with less overlap on CYP3A4-related pathways than alprazolam. This means lorazepam still suppresses melatonin production and depletes magnesium through GABAergic effects, but its minimal CYP3A4 induction may slow the rate of vitamin D catabolism compared to alprazolam.
Lorazepam has 90% oral bioavailability with peak concentration at 2 hours and a half-life of 10–20 hours (average 14 hours), providing slightly more sustained blood levels than alprazolam with fewer peak-trough fluctuations.
- ✓Glucuronidation metabolism avoids CYP450 drug interactions — safer in polypharmacy patients
- ✓Minimal CYP3A4 induction may preserve vitamin D levels better than alprazolam
- ✓Available in IV and IM forms for acute situations (status epilepticus, procedural sedation)
- ✓Slightly longer half-life provides smoother symptom coverage between doses
- ✗FAERS documents 126,712 adverse event reports with a 20.4% death-associated rate — the highest among common benzodiazepines
- ✗Higher protein binding (85%) increases accumulation risk in hepatic or renal impairment
- ✗Amnestic effects are more pronounced than alprazolam, particularly at higher doses
- ✗Slower onset (30–60 minutes oral) may tempt patients to take additional doses prematurely
Patients on multiple medications where CYP450 drug interactions are a concern, or those needing an injectable benzodiazepine option for acute care settings.
Feature Comparison
| Feature | Alprazolam | Lorazepam |
|---|---|---|
| Drug Class | Triazolobenzodiazepine | 3-Hydroxy benzodiazepine |
| Nutrients Depleted | 4 — melatonin, vitamin D, calcium, magnesium | 4 — melatonin, vitamin D, calcium, magnesium |
| Half-Life | 11.2 hours | 10–20 hours (avg 14) |
| Primary Metabolism | CYP3A4 (hepatic oxidation) | Direct glucuronidation (no CYP) |
| CTD Gene Interactions | 78 documented | 50 documented |
| FAERS Reports | 116,446 (18.1% death-associated) | 126,712 (20.4% death-associated) |
| Available Forms | Oral tablets, oral disintegrating | Oral, IV, IM injection |
| Primary Indications | Panic disorder, generalized anxiety | Anxiety, pre-procedure sedation, status epilepticus |
Wondering which medication depletes less?
Check your medications free — 10 seconds →Verdict
Neither drug wins on nutrient depletion — both drain the same four nutrients through identical GABA-A mechanisms. The meaningful difference is metabolic pathway. Alprazolam's heavy CYP3A4 dependence means more drug interactions and potentially faster vitamin D clearance, while lorazepam's glucuronidation pathway avoids CYP interactions entirely, making it the safer choice for patients on multiple medications. However, FAERS safety data gives pause: lorazepam's 126,712 reports carry a 20.4% death-associated rate compared to alprazolam's 18.1% across 116,446 reports. For nutrient protection specifically, lorazepam's CYP-sparing metabolism may offer a slight edge on vitamin D preservation, but consistent supplementation matters far more than which benzodiazepine you choose.
FAQ
References
- [1]CTD (Comparative Toxicogenomics Database): 78 gene interactions for alprazolam including CYP3A4 and GABA receptor subunits; 50 gene interactions for lorazepam
- [2]ChEMBL bioactivity database: 208 randomized controlled trials for alprazolam across 30,200 enrolled patients
- [3]FAERS (FDA Adverse Event Reporting System): 116,446 alprazolam reports (18.1% death-associated), 126,712 lorazepam reports (20.4% death-associated)
- [4]PharmGKB pharmacogenomics database: CYP3A4 Level 3 evidence annotations for alprazolam; glucuronidation pathway annotations for lorazepam
- [5]PubMed PMID 28893045 — Lader M. Benzodiazepines revisited: will we ever learn? Addiction. 2011;106(12):2086-2109
Check your medications
Check Free →